本文選題：分化型甲狀腺癌 + RAS基因�。� 參考：《昆明醫(yī)科大學(xué)》2017年碩士論文

【摘要】：[目的]檢測分化型甲狀腺癌中KRAS基因突變率;分析分化型甲狀腺癌中KRAS基因突變率與患者年齡、性別、病理類型、被膜浸潤、遠處轉(zhuǎn)移之間是否存在相關(guān)性;判斷KRAS基因突變能否作為指導(dǎo)臨床治療及判斷預(yù)后的指標(biāo)。[方法]選擇2013年01月至2016年12月符合入組的患者44例,選取其存檔在昆明醫(yī)科大學(xué)第三附屬醫(yī)院病理科的石蠟包埋組織,每位患者切白片5張,確定含有腫瘤組織;記錄所有研究對象的腫瘤大小、病理分型、被膜浸潤、遠處轉(zhuǎn)移等與之相關(guān)的臨床病理資料;運用“人類KRAS基因突變檢測試劑盒(熒光PCR法)”行KRAS基因突變檢測,該試劑盒涵蓋KRAS基因2、3、4外顯子的11個熱點突變,基于擴增阻礙突變系統(tǒng)(Amplification Refractory Mutation System,ARMS)和熒光PCR技術(shù)實現(xiàn)樣本DNA中KRAS基因的突變檢測。[結(jié)果]本研究檢測了 44例分化型甲狀腺癌患者的常見KRAS基因熱點突變,均未發(fā)現(xiàn)存在KRAS基因熱點突變,本課題尚存在不足:樣本地域性局限和數(shù)量偏少。[結(jié)論]分化型甲狀腺癌組織中KRAS基因常見熱點無突變;分化型甲狀腺癌患者的年齡、性別、病理類型、被膜浸潤、遠處轉(zhuǎn)移與KRAS基因的突變可能無顯著相關(guān)性,暫不能作為判斷分化型甲狀腺癌的預(yù)后指標(biāo)。
[Abstract]:[objective] to detect the mutation rate of KRAS gene in differentiated thyroid carcinoma, and to analyze the correlation between the mutation rate of KRAS gene and age, sex, pathological type, membrane infiltration and distant metastasis in differentiated thyroid carcinoma. To determine whether the mutation of KRAS gene can be used as a guideline for clinical treatment and prognosis. [methods] A total of 44 patients from January 2013 to December 2016 were selected and paraffin embedded tissues were selected from the Department of Pathology of the third affiliated Hospital of Kunming Medical University. 5 pieces of white slices were cut from each patient to determine the presence of tumor tissue. The clinical and pathological data of tumor size, pathological type, membrane infiltration and distant metastasis were recorded, and KRAS gene mutation was detected by "human KRAS gene mutation detection kit (fluorescent PCR method)". The kit covers 11 hot spot mutations in exon 2O3O4 of KRAS gene. The mutation detection of KRAS gene in sample DNA is realized based on Amplification Refractory Mutation system and fluorescence PCR technique. [results] in this study, common KRAS gene hot spot mutations were detected in 44 patients with differentiated thyroid carcinoma. None of them found hot spot mutations of KRAS gene. [conclusion] there is no common hot spot mutation of KRAS gene in differentiated thyroid carcinoma, and there may be no significant correlation between age, sex, pathological type, membrane infiltration, distant metastasis and mutation of KRAS gene in differentiated thyroid carcinoma. It can not be used as prognostic index of differentiated thyroid carcinoma for the time being.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R736.1

【參考文獻】

相關(guān)期刊論文 前8條

1 李小毅;;2015年美國甲狀腺學(xué)會《成人甲狀腺結(jié)節(jié)與分化型甲狀腺癌診治指南》解讀:外科部分[J];中國癌癥雜志;2016年01期

2 劉敏;陳立波;;~(131)I難治性分化型甲狀腺癌分子靶向治療進展[J];臨床腫瘤學(xué)雜志;2015年06期

3 郝智;崔建英;;分化型甲狀腺癌相關(guān)基因的研究進展[J];現(xiàn)代腫瘤醫(yī)學(xué);2015年04期

4 任思佳;沈捷;;食鹽加碘對甲狀腺癌發(fā)病的影響[J];醫(yī)學(xué)綜述;2014年17期

5 孫嘉偉;許曉君;蔡秋茂;許燕君;顧江;;中國甲狀腺癌發(fā)病趨勢分析[J];中國腫瘤;2013年09期

6 易文君;鐘德s，

本文編號：1804695